Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,300.00
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change138.53%
  • Beta1.8453
Data delayed at least 20 minutes, as of Nov 22 2024 08:01 GMT.
More ▼

Profile data is unavailable for this security.

About the company

4basebio PLC is a United Kingdom-based biotechnology company. The Company is focused on life sciences and in particular the development of synthetic Deoxyribonucleic acid (DNA) and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for cell and gene therapies and vaccines. It is engaged in the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads in patients. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications.

  • Revenue in GBP (TTM)596.00k
  • Net income in GBP-9.84m
  • Incorporated2020
  • Employees--
  • Location
    4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
  • Phone+44 12 2396 7943
  • Websitehttps://www.4basebio.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.0036.26m11.00
Poolbeg Pharma PLC0.00-4.38m38.00m8.0038.00m8.00
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Puretech Health PLC371.84k-65.52m389.83m90.00389.83m90.00
Oxford BioMedica plc97.28m-142.02m436.93m834.00436.93m834.00
Data as of Nov 22 2024. Currency figures normalised to 4Basebio PLC's reporting currency: UK Pound GBX

Institutional shareholders

37.75%Per cent of shares held by top holders
HolderShares% Held
M&G Investment Management Ltd.as of 12 Nov 20244.63m36.12%
Aramea Asset Management AGas of 30 Jun 2022143.33k1.12%
Deutsche Bank AG (Private Banking Germany)as of 30 Sep 202451.67k0.40%
DWS Investment GmbHas of 30 Aug 202413.36k0.10%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.